Compare Stocks: AFMD, EGRX, KPRX, and ADIL

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADIL Adial Pharmaceuticals	$4.44 +9.9%	$4.70	$1.31 ▼ $10.75	$11.03M	1.38	49,645 shs	47,312 shs
AFMD Affimed	$0.18	$0.25	$0.07 ▼ $1.13	$2.92M	2.07	51.16 million shs	N/A
EGRX Eagle Pharmaceuticals	$0.90	$0.63	$0.00 ▼ $3.00	$23.38M	0.83	7,795 shs	4,110 shs
KPRX Kiora Pharmaceuticals	$2.67 +1.9%	$2.59	$1.76 ▼ $2.95	$11.99M	-0.34	14,033 shs	19,375 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADIL Adial Pharmaceuticals	-3.81%	-22.90%	-25.19%	+56.59%	-53.00%
AFMD Affimed	0.00%	0.00%	0.00%	0.00%	0.00%
EGRX Eagle Pharmaceuticals	0.00%	-29.96%	+69.81%	+50.00%	-73.29%
KPRX Kiora Pharmaceuticals	-3.32%	+0.77%	-4.73%	+2.75%	+3.15%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADIL Adial Pharmaceuticals	$4.44 +9.9%	$4.70	$1.31 ▼ $10.75	$11.03M	1.38	49,645 shs	47,312 shs
AFMD Affimed	$0.18	$0.25	$0.07 ▼ $1.13	$2.92M	2.07	51.16 million shs	N/A
EGRX Eagle Pharmaceuticals	$0.90	$0.63	$0.00 ▼ $3.00	$23.38M	0.83	7,795 shs	4,110 shs
KPRX Kiora Pharmaceuticals	$2.67 +1.9%	$2.59	$1.76 ▼ $2.95	$11.99M	-0.34	14,033 shs	19,375 shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADIL Adial Pharmaceuticals	-3.81%	-22.90%	-25.19%	+56.59%	-53.00%
AFMD Affimed	0.00%	0.00%	0.00%	0.00%	0.00%
EGRX Eagle Pharmaceuticals	0.00%	-29.96%	+69.81%	+50.00%	-73.29%
KPRX Kiora Pharmaceuticals	-3.32%	+0.77%	-4.73%	+2.75%	+3.15%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADIL Adial Pharmaceuticals	2.40	Hold	$15.63	251.91% Upside
AFMD Affimed	0.00	N/A	N/A	N/A
EGRX Eagle Pharmaceuticals	0.00	N/A	N/A	N/A
KPRX Kiora Pharmaceuticals	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest AFMD, EGRX, KPRX, and ADIL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/3/2026	ADIL Adial Pharmaceuticals	Alliance Global Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$11.00
7/17/2026	ADIL Adial Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/14/2026	KPRX Kiora Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/26/2026	KPRX Kiora Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 9/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADIL Adial Pharmaceuticals	N/A	N/A	N/A	N/A	$4.75 per share	N/A
AFMD Affimed	$877K	3.33	N/A	N/A	$4.19 per share	0.04
EGRX Eagle Pharmaceuticals	$257.55M	0.05	$2.25 per share	0.40	N/A	∞
KPRX Kiora Pharmaceuticals	$16.02M	0.74	N/A	N/A	$4.38 per share	0.61

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADIL Adial Pharmaceuticals	-$7.98M	-$14.73	N/A	N/A	N/A	N/A	-203.87%	-512.41%	11/18/2026 (Estimated)
AFMD Affimed	-$114.66M	N/A	N/A	N/A	N/A	-7,836.26%	-193.84%	-107.24%	N/A
EGRX Eagle Pharmaceuticals	$35.64M	$1.18	0.76	N/A	N/A	N/A	N/A	N/A	11/9/2026 (Estimated)
KPRX Kiora Pharmaceuticals	-$10.84M	-$2.51	N/A	N/A	N/A	N/A	-63.38%	-44.33%	11/6/2026 (Estimated)

Latest AFMD, EGRX, KPRX, and ADIL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/14/2026	Q2 2026	ADIL Adial Pharmaceuticals	-$1.0325	-$11.25	-$10.2175	-$11.25	N/A	N/A
8/7/2026	Q2 2026	KPRX Kiora Pharmaceuticals	-$0.47	-$0.34	+$0.13	-$0.34	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADIL Adial Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
AFMD Affimed	N/A	N/A	N/A	N/A	N/A
EGRX Eagle Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
KPRX Kiora Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADIL Adial Pharmaceuticals	N/A	5.63	5.63
AFMD Affimed	0.13	1.93	1.93
EGRX Eagle Pharmaceuticals	N/A	N/A	N/A
KPRX Kiora Pharmaceuticals	N/A	8.97	8.97

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADIL Adial Pharmaceuticals	16.41%
AFMD Affimed	30.82%
EGRX Eagle Pharmaceuticals	85.36%
KPRX Kiora Pharmaceuticals	76.97%

Insider Ownership

Company	Insider Ownership
ADIL Adial Pharmaceuticals	8.00%
AFMD Affimed	3.80%
EGRX Eagle Pharmaceuticals	28.90%
KPRX Kiora Pharmaceuticals	0.52%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADIL Adial Pharmaceuticals	6	2.63 million	2.42 million	No Data
AFMD Affimed	200	16.10 million	15.49 million	No Data
EGRX Eagle Pharmaceuticals	100	12.99 million	9.23 million	No Data
KPRX Kiora Pharmaceuticals	13	4.42 million	4.40 million	Not Optionable

AFMD, EGRX, KPRX, and ADIL Headlines

Recent News About These Companies

Aditxt (NASDAQ:ADTX) versus Kiora Pharmaceuticals (NASDAQ:KPRX) Head-To-Head Survey

September 14, 2026 | americanbankingnews.com

Kiora Pharmaceuticals Appoints Keith J. Lane as Executive Vice President of Global Clinical Development and Regulatory Affairs

September 8, 2026 | finance.yahoo.com

Kiora Pharmaceuticals Licenses South Korean Ophthalmic Development and Commercialization Rights for KIO-301 to Chong Kun Dang Pharmaceutical Corporation

August 19, 2026 | newsfilecorp.comN

Analysts Have Conflicting Sentiments on These Healthcare Companies: Joint (JYNT) and Kiora Pharmaceuticals (KPRX)

August 9, 2026 | theglobeandmail.com

Kiora Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 7, 2026 | newsfilecorp.comN

Kiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium

July 2, 2026 | newsfilecorp.comN

Kiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model

June 18, 2026 | newsfilecorp.comN

Kiora Pharmaceuticals Shareholders Approve Expanded Equity Incentive Plan

June 11, 2026 | tipranks.com

Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 8, 2026 | finanznachrichten.de

Kiora Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 8, 2026 | newsfilecorp.comN

Kiora’s phase 1 ABACUS study of KIO-301 in retinitis pigmentosa published in Nature Medicine; phase 2 trial underway

April 15, 2026 | eurekalert.orgE

Kiora's Phase 1 ABACUS Study of KIO-301 in Retinitis Pigmentosa Published in Nature Medicine; Phase 2 Trial Underway

April 14, 2026 | newsfilecorp.comN

Kiora's KIO-301 Study in Retinitis Published, Phase 2 On

April 14, 2026 | miragenews.comM

Why did KPRX stock surge 17% pre-market today?

April 7, 2026 | msn.com

Kiora Pharmaceuticals Announces Private Placement for Up to $24 Million Led by Perceptive Advisors

April 7, 2026 | finance.yahoo.com

Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals Announces Private Placement for Up to $24 Million Led by Perceptive Advisors

April 7, 2026 | finanznachrichten.de

Kiora Pharmaceuticals Announces Chief Development Officer Resignation

April 5, 2026 | theglobeandmail.com

Kiora Pharmaceuticals Announces Management Team Changes

April 2, 2026 | newsfilecorp.comN

Kiora Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Results; Company Advances Retinal Disease Pipeline with Two Active Phase 2 Clinical Trials

March 25, 2026 | newsfilecorp.comN

Kiora Pharmaceuticals to Present at Oppenheimer's 36th Annual Healthcare Life Sciences Conference

February 19, 2026 | newsfilecorp.comN

New MarketBeat Followers Over Time

Media Sentiment Over Time

AFMD, EGRX, KPRX, and ADIL Company Descriptions

Adial Pharmaceuticals NASDAQ:ADIL

$4.44 +0.40 (+9.90%)

Closing price 04:00 PM Eastern

Extended Trading

$4.69 +0.25 (+5.63%)

As of 07:55 PM Eastern

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

Affimed NASDAQ:AFMD

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid. It develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. It has collaboration with Artiva Biotherapeutics to develop the combination of acimtamig and AlloNK; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and strategic collaboration agreement with Genentech for the development of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Mannheim, Germany.

Eagle Pharmaceuticals NASDAQ:EGRX

$0.90 0.00 (0.00%)

As of 02:35 PM Eastern

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.

Kiora Pharmaceuticals NASDAQ:KPRX

$2.67 +0.05 (+1.91%)

Closing price 04:00 PM Eastern

Extended Trading

$2.64 -0.04 (-1.31%)

As of 04:10 PM Eastern

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, and KIO-104 for the treatment of posterior non-infectious uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AFMD, EGRX, KPRX, and ADIL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AFMD, EGRX, KPRX, and ADIL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AFMD, EGRX, KPRX, and ADIL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AFMD, EGRX, KPRX, and ADIL Company Descriptions

Adial Pharmaceuticals NASDAQ:ADIL

Affimed NASDAQ:AFMD

Eagle Pharmaceuticals NASDAQ:EGRX

Kiora Pharmaceuticals NASDAQ:KPRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AFMD, EGRX, KPRX, and ADIL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AFMD, EGRX, KPRX, and ADIL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AFMD, EGRX, KPRX, and ADIL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AFMD, EGRX, KPRX, and ADIL Company Descriptions

Adial Pharmaceuticals NASDAQ:ADIL

Affimed NASDAQ:AFMD

Eagle Pharmaceuticals NASDAQ:EGRX

Kiora Pharmaceuticals NASDAQ:KPRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools